


## Ragaglitazar

## Chemical Properties

CAS No. :	222834-30-2
Formula:	C <sub>25</sub> H <sub>25</sub> N <sub>1</sub> O <sub>5</sub>
Molecular Weight:	419.47
Storage:	Store at low temperature Powder: -20°C for 3 years   In solvent: -80°C for 1 year <i>Actual storage temperature shall be subject to the COA.</i>



## Biological Description

Description	Ragaglitazar(NNC-61-0029) is a potent dual activator of PPAR $\gamma$ and PPAR $\alpha$ , which shows improved insulin sensitization and lipid-lowering potential in animal models and can be used to study type 2 diabetes.
Targets(IC50)	PPAR
In vitro	<b>METHODS:</b> A comparative dose-response study of PPAR $\gamma$ and PPAR $\alpha$ was performed using Ragaglitazar (NNC-61-0029) (0.1, 1, 10, 100 nM). <b>RESULTS</b> Ragaglitazar (NNC-61-0029) showed significant activation of both isoforms. Ragaglitazar showed weaker potency against PPAR $\gamma$ (EC <sub>50</sub> =324 nm) and more potent activation of PPAR $\alpha$ (EC <sub>50</sub> =270 nm). [1]
In vivo	<b>METHODS:</b> SD rats fed a high-fat diet were treated with Ragaglitazar (NNC-61-0029) (0.1, 0.3, 1, 10, 30 mg/kg) to observe the improvement of blood lipid levels in rats. <b>RESULTS</b> Rats showed a dose-dependent improvement in plasma lipid levels, and plasma Apo CIII levels were significantly reduced in ragaglitazar (10 mg/kg) (P<0.05). [1]

## Solubility Information

Solubility	DMSO: 50 mg/mL (119.2 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2.5 mg/mL (5.96 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	<b>1mg</b>	<b>5mg</b>	<b>10mg</b>
1 mM	2.384 mL	11.9198 mL	23.8396 mL
5 mM	0.4768 mL	2.384 mL	4.7679 mL
10 mM	0.2384 mL	1.192 mL	2.384 mL
50 mM	0.0477 mL	0.2384 mL	0.4768 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Chakrabarti R, Vikramadithyan RK, Misra P, et al. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. *Br J Pharmacol.* 2003;140(3):527-537.  
Saad MF, Greco S, Osei K, et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. *Diabetes Care.* 2004;27(6):1324-1329.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481